BIOMERICA INC (BMRA) — Analysis Summary
BIOMERICA INC (BMRA) has a market cap of $5.22M with year-over-year revenue growth of -1.9%. Net margin stands at -93.6%. The stock trades at a P/E ratio of -1.3.
Key Takeaways
- Revenue changed -1.9% year-over-year
- Net margin of -93.6%
- P/E ratio of -1.3
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, BMRA posted revenue growth of -1.9% and trades at a P/E of -1.3.
BIOMERICA INC (BMRA)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -123.7% — severe operating losses
Net margin at -96.5% — significant losses
Revenue declined 18.5% vs the prior period.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
54
Headquarters
IRVINE, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.